48 results
6-K
EX-99.2
NCNA
NuCana plc
13 May 24
Current report (foreign)
4:13pm
No. 03308778
U.K.
Contents
Strategic report
Directors’ report
Directors’ remuneration report
Statement of directors’ responsibilities
Independent … biliary tract cancer. This decision was made following a pre-planned futility analysis by the study’s Independent Data Monitoring Committee. Although
6-K
EX-99.2
NCNA
NuCana plc
15 May 23
Current report (foreign)
4:11pm
.
Contents
Strategic report
Directors’ report
Directors’ remuneration report
Statement of directors’ responsibilities
Independent auditor’s report … locally advanced or metastatic biliary tract cancer. This decision was made following a pre-planned futility analysis by the study’s Independent Data
6-K
EX-99.2
89llq yebl4
2 Jun 22
Unaudited Condensed Consolidated Statements of Operations
4:05pm
6-K
EX-99.1
0d3bfuv 0v
2 Mar 22
NuCana Announces Update for Phase 3 Biliary Tract Cancer Study
4:05pm
F-3
EX-1.2
867ck
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
9exg8kz45vnb t4k
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
EX-4.6
3jieg3s0
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
EX-4.7
90tft1b15b0
19 Aug 21
Shelf registration (foreign)
4:50pm
F-3
EX-23.1
vx0405kjv 0vrq
19 Aug 21
Shelf registration (foreign)
4:50pm
6-K
EX-99.3
tkram
19 Aug 21
Unaudited Condensed Consolidated Statements of Operations
4:28pm
6-K
EX-1.1
wo92u2i
18 Sep 20
NuCana Announces Pricing of a Public Offering of American Depositary Shares
4:15pm
424B5
ppf1i8 k35x5c
17 Sep 20
Prospectus supplement for primary offering
4:50pm